Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the role of CD133 in colon cancer, we silenced CD133 in human colon cancer cells.
|
31736063 |
2020 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our present observations strongly suggest that the CD133-PTPRK axis plays a pivotal role in the regulation of colon cancer progression as well as drug resistance.
|
30947381 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 was considered colon cancer stem cell marker and used to sort CD133+ and CD133- cells by magnetic cell sorting.
|
31390540 |
2019 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using three independent primary spheroidal colon cancer cultures that expressed a Wnt reporter construct we observed high Wnt activity was associated with the cell surface markers CD133, CD166, and CD29, but not CD24 and CD44, while the original study found all five markers were correlated with high Wnt activity (Figure 2F; Vermeulen et al., 2010).
|
31215867 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The colon cancer stem cells were successfully sorted, and the content of CD133+ in colon cancer stem cells reached 80.3%.
|
30941956 |
2019 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD133 expression was evaluated by flow cytometry in three colon cancer cell lines (HCT116, Lovo and DLD1).
|
27387378 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133-containing MVs induced the development of chemoresistance by abolishing the inhibitory effects of anti-epidermal growth factor receptor (EGFR) drugs on cell proliferation and motility in colon cancer.
|
30521383 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133+ colon cancer cells (LoVo) were infected with the lentiviral vector carrying CD133 gRNA and purified cell by culturing single cell colonies.
|
31393941 |
2019 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the whole, our data indicated that patients with colon cancer with CD133-negative expression had a reduced disease-free survival.
|
29328371 |
2018 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that RAC3 overexpression was mainly associated to CD133+ side-population of colon cancer cells and also to early and advanced stages of colon cancer, involving increased expression of mesenchymal and stem markers.
|
29464039 |
2018 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although the <i>TP53</i> gene is frequently mutated in colon cancer, it remains not fully understood whether and how tumor protein p53 (p53) is associated with CD133 expression in colon cancer cells.
|
29928431 |
2018 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, p-STAT3 may participate in the progression of the early stage of colon cancer through the up-regulation of CD133, which in turn induces survivin expression.
|
29432737 |
2018 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although less cytotoxic, the free ligand inhibits the surface marker CD133 expression in hepatocarcinoma cells, and in HT-29 colon carcinoma.
|
28358339 |
2017 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Assessment of neutralizing interleukin-4 effect on CD133 gene expression in colon cancer cell line.
|
28578295 |
2017 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, sorted CD133+ colon cancer cells exhibit no increased resistance to 5-FU, and CD133 levels exhibit no correlation with colon cancer patient survival or cancer recurrence.
|
27659530 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, using a human colon carcinoma HT-29 model, we demonstrated that the intratumoral (64)Cu-ATSM high-uptake regions exhibited malignant characteristics, such as upregulated DNA repair and elevated %CD133(+) cancer stem-like cells.
|
26996296 |
2016 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD133 and CD44 were regarded as markers of CCSCs and they were found to be co-expressed in the HCT116 colon cancer cell line.
|
27600678 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, CD44(high)/CD133(high) cells isolated from HCT-116 cells harbor CSC properties that may be related to the tumor growth of colon cancer.
|
26840024 |
2016 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To elucidate the role of CD133 expression in chemoresistance, we silenced the CD133 expression in a colon cancer cell line and determined its effect on the biological characteristics downstream.
|
26002465 |
2015 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our findings indicate that FOXM1, PRDX3, and CD133 are potential therapeutic targets for the elimination of CSCs in colon cancer.
|
26350748 |
2015 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
|
25625240 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we evaluate and comparing nucleostemin expression in CD133+ and CD133- colon cancer cell line HT29.
|
24762489 |
2014 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD66c was absent in CD133-positive cells that were isolated from normal colon, whereas its expression was brightest (CD66c(bright) ) in CD133-positive cells from colon cancer samples.
|
23027178 |
2013 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest CD133, a surface protein widely used for isolation of colon cancer stem cells, to be associated with tumor angiogenesis and recurrence.
|
22231565 |
2013 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133-positive cancer stem cells in colon cancer are resistant to conventional chemotherapy.
|
23245395 |
2013 |